One of our pass pick that we are still holding on but we recommend not to add weight due to its extreme diversification plan. It has reported flat revenue and profit of approximately RM 0.11. With a quarter to go, if a slight profit will bring the PE back below 10 times. We always like its auto part industry niche play. However, diversifying into healthcare business is yet to see if it can contribute back to its investment. We continue recommend a hold but we do not plan to buy in more at the moment.
Analabs result is disappointing with gross loss and lower revenue recorded for the quarter. Nothing to cheer with only properties revaluation exercise carried out with net values added to its NTA to RM 3.60. We will continue to monitor its performance from now before making next recommended suggestion.